Journal: ACS Nano Medicine

Article Title: CompELS vs SELEX: Comparative Aptamer Discovery Integrating Rational Libraries and Enzymatic Elution

doi: 10.1021/acsnanomed.6c00140

Figure Lengend Snippet: Top Six Aptamer Candidate Sequences (Seq1–Seq6) and One Low-Frequency Sequence (Seq7) Identified Following the Completion of SELEX and CompELS Screening

Article Snippet: Despite the moderate success of the first FDA-approved aptamer, Macugen, which was later discontinued, the widespread clinical and commercial translation of aptamers has been further hindered by challenges in their discovery process.

Techniques: Sequencing, Screening

Journal: ACS Nano Medicine

Article Title: CompELS vs SELEX: Comparative Aptamer Discovery Integrating Rational Libraries and Enzymatic Elution

doi: 10.1021/acsnanomed.6c00140

Figure Lengend Snippet: Enrichment dynamics of the top six sequences. Comparison of sequence enrichment (Reads Per Million, RPM) over 14 SELEX enrichment cycles (dotted lines) and two enrichment cycles following completion of each of two CompELS stages (solid lines). The inset magnifies critical early cycles (0–4) to pinpoint aptamer emergence for each selection platform.

Article Snippet: Despite the moderate success of the first FDA-approved aptamer, Macugen, which was later discontinued, the widespread clinical and commercial translation of aptamers has been further hindered by challenges in their discovery process.

Techniques: Comparison, Sequencing, Selection

Journal: ACS Nano Medicine

Article Title: CompELS vs SELEX: Comparative Aptamer Discovery Integrating Rational Libraries and Enzymatic Elution

doi: 10.1021/acsnanomed.6c00140

Figure Lengend Snippet: Comparative enrichment dynamics of structurally distinct screening libraries within aptamer screening pools as a function of enrichment cycle during CompELS (dashed lines) and SELEX (solid lines). The percentage of sequences originating from the Standard (dark blue), Empirical (light blue), Tetraloop (green), and Unmatched (yellow) within the total pool determined by NGS analysis of barcode identities.

Article Snippet: Despite the moderate success of the first FDA-approved aptamer, Macugen, which was later discontinued, the widespread clinical and commercial translation of aptamers has been further hindered by challenges in their discovery process.

Techniques: Screening, Analysis

Journal: ACS Nano Medicine

Article Title: CompELS vs SELEX: Comparative Aptamer Discovery Integrating Rational Libraries and Enzymatic Elution

doi: 10.1021/acsnanomed.6c00140

Figure Lengend Snippet: Binding affinity of selected aptamer candidates for mCherry. Electrophoretic mobility shift assay (EMSA) binding curves for the top six enriched sequences (Seq1–Seq6) and one low-enrichment representative (Seq7) against mCherry. Error bars represent standard deviation of three samples.

Article Snippet: Despite the moderate success of the first FDA-approved aptamer, Macugen, which was later discontinued, the widespread clinical and commercial translation of aptamers has been further hindered by challenges in their discovery process.

Techniques: Binding Assay, Electrophoretic Mobility Shift Assay, Standard Deviation

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Niemann-Pick type C1 protein regulates epidermal growth factor receptor stability in hepatic cells and facilitates the early steps of Hepatitis B virus infection

doi: 10.3389/fcimb.2026.1905331

Figure Lengend Snippet: FDA-approved NPC1 inhibitors reduce HBV entry. (A) HepG2-hNTCP cells were treated with either itraconazole, posaconazole, verapamil, amiodarone at the indicated concentrations, or DMSO for 24 h prior to HBV inoculation (300 GEq/cell). Secreted HBeAg levels were quantified by ELISA at 7 dpi. (B) Drug toxicity was evaluated by MTS assay, after 24 h of incubation. Data are presented as mean ± SD percentages from DMSO controls from three (A) or two (B) independent experiments performed in at least two biological replicates. Statistical significance was determined by using one-way ANOVA (****p < 0.0001, ns, not significant).

Article Snippet: Cells were treated with U18666A (MedchemExpress, 3039-71-2) or various FDA-approved drugs (TargetMoi, L4200), at concentrations indicated in figure captions, for 24 h prior to HBV infection.

Techniques: Enzyme-linked Immunosorbent Assay, MTS Assay, Incubation